#ESMO26 | VIKTORIA-1 –Study 2— Updated Results

In PIK3CA-mutant HR+/HER2− advanced breast cancer, gedatolisib + fulvestrant + palbociclib maintained its PFS benefit over alpelisib + fulvestrant (9.8 vs 5.6 months; HR 0.52). Median PFS was 11.1 months at ASCO26.

The benefit was observed with and without visceral metastases (HR 0.38 and 0.46, respectively).

The contribution of palbociclib remains unclear, and IV administration continues to be a practical limitation.